We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Proteome Sciences Plc | PRM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.06 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.06 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 17/3/2025 10:29 by base7 Would PRM be interested in buying any "cheap "asset of Oncimmune from The Administrator ? |
Posted at 09/3/2025 13:19 by wrighty41 Z1CO - I tend to agree with you that the opportunity for PRM may be ‘now’! However I’m waiting to read the forward looking statement with the results before I get too excited.Whatever the outlook I am expecting the shares to finish north of my initial 6p target by Y/E, how much north who knows! W41 |
Posted at 03/3/2025 19:46 by gnnmartin Barry (post 59925) I assumed that the PRM advances enable users to do more with the same machine, so the fact that there has been 'no detectable increase in demand' for Mass Spec machines does not mean that PRM's offerings are not in demand.But I am just (optimistically) guessing. |
Posted at 02/3/2025 16:05 by wellhonedhutch Hi all - It was recently announced that PRM is in discussions with a shortlist of companies interested in securing licences for PRM's new Multiplex DIA tags, I note it suggests licences are expected to conclude in H1 2025. Do you feel that there would be an up front fee from any successful licensee(s)? Hutch |
Posted at 23/2/2025 16:27 by wrighty41 Z1CO, I certainly agree that the near & medium term prospects for PRM do look brighter than at any time over the last few years.W41 |
Posted at 21/2/2025 23:16 by elpirata peverill will be impressed to note that Pike has not been idleBit ironic that the prm share price has suffered the same affliction for years |
Posted at 21/2/2025 07:56 by barry evans Absolutely.Well done PRM, the chickens will be fed for the days to come. FFS, what a complete shower. I guess that RNS can be best filed in the folder 'Tell me you are not a serious business without telling me you are not a serious business'. |
Posted at 21/2/2025 07:11 by wrighty41 Well done PRM.Revenue & profit expectations in 2025 will drive the share price higher & certainty too (& maybe beyond) my 6p price target. W41 |
Posted at 05/1/2025 14:47 by wellhonedhutch Welcome ZICO - Thank you for your posts which have been very helpful and a breath of fresh air. I do think it is time to buy more on the PRM statement and that the move to America is apparently going so well. I am also encouraged by the £500,000 contract awarded, with the prospect of more from that same company and contracts from others. However many us who have been bulls over the years have been disappointed so often. Maybe this is the moment for PRM to move forward and enjoy the momentum of the Proteomic market growing into the future. PRM certainly have some good products and we are in the right area. Hopefully Stroke may come good to this year. How I would love to see this. |
Posted at 22/7/2024 11:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
